Here is the original post:

CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh